Characteristics of Brazilian melanomas: real-world results before and after the introduction of new therapies.

Autor: da Costa LMM; Barretos School of Health Sciences, Dr. Paulo Prata, Medicine, Barretos, SP, Brazil., Crovador CS; Department of Surgery, Melanoma, Sarcoma and Mesenchymal Tumors, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, SP, 14784-400, Brazil., de Carvalho CEB; Department of Surgery, Melanoma, Sarcoma and Mesenchymal Tumors, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, SP, 14784-400, Brazil., Vazquez VL; Department of Surgery, Melanoma, Sarcoma and Mesenchymal Tumors, Barretos Cancer Hospital, Antenor Duarte Villela, 1331, Barretos, SP, 14784-400, Brazil. viniciusvazquez@gmail.com.
Jazyk: angličtina
Zdroj: BMC research notes [BMC Res Notes] 2019 May 28; Vol. 12 (1), pp. 296. Date of Electronic Publication: 2019 May 28.
DOI: 10.1186/s13104-019-4336-7
Abstrakt: Objective: This study is a characterization of the treatment patterns and outcomes of a Brazilian melanoma cohort collected of 1848 patients enrolled between 1996 and 2015.
Results: The superficial spreading subtype (35.1%) was the most prevalent, and the favoured anatomical location was the trunk (32.8%). The most common clinical stage was I (27.6%). The most frequent initial treatment was surgery (84.7%). Sentinel node biopsy was positive in 23.3% of cases. Chemotherapy was used to treat 298 patients (16.1%), immunotherapy for 67 (3.6%) and targeted therapy for 19 (1.0%). Distant recurrence was commonly observed (22.5%) and the mutation status of the BRAF gene was verified in 132 cases, with 42.4% positivity in this subset of patients. The melanoma specific actuarial 5-year survival for the cohort was 68.8%. There was a higher 5-year survival observed in metastatic melanoma patients who received immunotherapy and/or targeted therapy (34.2%) compared patients treated with just chemotherapy (20.0%). The survival analysis showed that sex, age, Breslow, clinical stage and distant recurrence were significant prognostic factors. This study provides a real-world description of how the introduction of new therapies such as immunotherapy and BRAF inhibitors is changing treatment strategies for melanoma in developing countries.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje